ArticleAnnals of general hospital psychiatry2004
A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia.
Article in Annals of general hospital psychiatry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Head-to-head comparison of the costs of atypical antipsychotics: a systematic review.CNS drugs · 2005Pooled it
- Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.BMC psychiatry · 2006Trial
- Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.BMC psychiatry · 2005Trial
- Personality dimensions of schizophrenia patients compared to control subjects by gender and the relationship with illness severity.BMC psychiatry · 2014Article
- Article
- The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Effectiveness studies: advantages and disadvantages.Dialogues in clinical neuroscience · 2011Review
- Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations.European archives of psychiatry and clinical neuroscience · 2010Article
- Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.Cost effectiveness and resource allocation : C/E · 2009Article
- Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia.BMC research notes · 2009Article
- Costs of treating patients with schizophrenia who have illness-related crisis events.BMC psychiatry · 2008Article
- Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia.Patient preference and adherence · 2008Article
- The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.Schizophrenia research · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDecreasing hospital admissions is important for improving outcomes for people with schizophrenia and for reducing cost of hospitalization, the largest expenditure in treating this persistent and severe mental illness. This prospective observational study compared olanzapine and risperidone on one-year psychiatric hospitalization rate, duration, and time to hospitalization in the treatment of patients with schizophrenia in usual care.
methodsWe examined data of patients newly initiated on olanzapine (N = 159) or risperidone (N = 112) who continued on the index antipsychotic for at least one year following initiation. Patients were participants in a 3-year prospective, observational study of schizophrenia patients in the US. Outcome measures were percent of hospitalized patients, total days hospitalized per patient, and time to first hospitalization during the one-year post initiation. Analyses employed a generalized linear model with adjustments for demographic and clinical variables. A two-part model was used to confirm the findings. Time to hospitalization was measured by the Kaplan-Meier survival formula.
resultsCompared to risperidone, olanzapine-treated patients had significantly lower hospitalization rates, (24.1% vs. 14.4%, respectively, p = 0.040) and significantly fewer hospitalization days (14.5 days vs. 9.9 days, respectively, p = 0.035). The mean difference of 4.6 days translated to $2,502 in annual psychiatric hospitalization cost savings per olanzapine-treated patient, on average.
conclusionsConsistent with prior clinical trial research, treatment-adherent schizophrenia patients who were treated in usual care with olanzapine had a lower risk of psychiatric hospitalization than risperidone-treated patients. Lower hospitalization costs appear to more than offset the higher medication acquisition cost of olanzapine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.